Artificial oocyte activation improves the laboratory and clinical outcome in vitrified donor oocyte group
DOI:
https://doi.org/10.37800/RM2021-1-5Keywords:
Donation, oocytes, usable blastocysts, artificial activation, IVF, infertilityAbstract
Introduction: Oocyte donation is proved effective. Vitrification of donor eggs allows creation of donor egg banking.
Simultaneously, for good clinical outcome it is recommended to thaw 10-15 oocytes at once. In the current study, we demonstrate the benefit of using artificial oocyte activation in order to reduce the number of thawed donor eggs for IVF program without any affect on laboratory and clinical outcome.
Aim of study: To improve the good quality blastocyst formation rate using artificial activation with vitrified donor eggs. Is
it possible to increase the clinical pregnancy rate (CPR) and live birth rate (LBR) thawing only 6-8 donor eggs?
Materials and Methods: The retrospective cohort studyincluded 40 fresh (Group A) and 12 vitrified (Group B) donor egg
programs. ICSI was conducted to all oocytes. In Group B, we also used artificial oocyte activation with calcium ionophore.
Student T test was used to infer statistical significance. P value < 0.05 was considered significant.
Results: The fertilization and good quality blastocyst formation rate is not different between the groups. The majority of
usable blastocysts, 72% in Group A and 93% in Group B were formed on Day 5. The CPR is not statistically different between
groups A and B and is 52.5% and 50% respectively. The IR is not statistically significant and is 39% in Group A and 42% in
Group B. The LBR is higher in Group A (50%) comparing to Group B (25%), but the difference is not statistically significant.
Conclusions:Considering our data, we suggest that artificial oocyte activation is feasible for use with vitrified donor eggs.
It might decrease the expenses of patients on thawing less number of donor oocytes without negative impact on the laboratory
and clinical outcome.
References
Cobo A., Meseguer M., Remohi J., Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Human Reproduction. 2010; 25(9); 2239-2246. Doi:10.1093/humrep/deq146.
Practice Committee of American Society for Reproductive Medicine and Practice Committee of Society of Assisted Reproduction Technology. 2008 guidelines for gamete and embryo donation: a practice committee report. Fertility Sterility. 2008; 90(5): S30-44. DOI: 10.1016/j.fertnstert.2008.08.090.
Kuwayama, M. Highly efficient vitrification for cryopreservation of human oocytes and embryos: the Cryotop method. Theriogenology. 2007; 67(1): 73-80. DOI: 10.1016/j.theriogenology.2006.09.014.
Rienzi L., Cobo A., Paffoni A., Scarduelli C., Capalbo A., Vajta G. et al. Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. Human Reproduction. 2012; 27(6): 1606-1612. DOI: 10.1093/humrep/des088.
Herrero L., Pareja S., Aragones M., Cobo A., Bronet F., Garcia-Velasco J.A. Oocyte versus embryo vitrification for delayed embryo transfer: an observational study. 2014; 29: 567-572. DOI:https://doi.org/10.1016/j.rbmo.2014.07.016.
Cobo A., Garrido N., Pellicer A., Remohi, J. Six years’ experience in ovum donation using vitrified oocytes: report of cumulative outcomes, impact of storage time, and development of a predictive model for oocyte survival rate. Fertility Sterility. 2015; 104(6): 1426-1434. DOI: 10.1016/j.fertnstert.2015.08.020.
Scott L., Alvero R., Leondires M., Miller, B. The morphology of human pronuclear embryos is positiviely related to blastocyst development and implantation. Human Reproduction. 2000; 15: 2394-2403. DOI:10.1093/humrep/15.11.2394.
Gardner D.K. and Schoolcraft W.B. In vitro culture of human blastocysts. In Jansen, R. and Mortimer, D. (eds). Toward Reproductive Certainty: Fertility and Genetics Beyond 1999. 1999a. London: Parthenon Publishing 378–388.
Gardner D.K. and Schoolcraft W.B. Culture and transfer of human blastocysts. Current Opinion in Obstetrics and Gynecology. 1999b; 11:307–331. DOI: 10.1097/00001703-199906000-00013.
Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. HumanReproduction. 2011; 26(6):1270–1283. https://doi.org/10.1093/humrep/der037.
Формулы для статистического анализа https://www.socscistatistics.com/tests/kolmogorov/default.aspx
Pouwer A.W., Farquhar C., Kremer J.A.M. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. 2012. DOI: 10.1002/14651858.CD009577.pub2.
Yovich J.L., Keane K.N., Borude G., Dhalival S.S., Hinchliffe P.M. Finding a place for corifollitropin within the PIVET FSH dosing algorithms. Reproductive Biomedicine Online. 2018; 36: 47-58. DOI: 10.1016/j.rbmo.2017.09.017.
De Los Santos M.J., Apter S., Coticchio G., Debrock S., Lundin K., Plancha C.E., Prados F., Rienzi L., Verheyen G., Woodward B., Vermeulen N. Revised guidelines for good practice in IVF laboratories. Human Reproduction. 2015; 31(4):685-6. doi: 10.1093/humrep/dew016. Epub 2016 Feb 17.
Vajta G., Rienzi L., Ubaldi, F.M. Open versus closed systems for vitrification of human oocytes and embryos. Reproductive BioMedicine Online. 2015; 30: 325-333. Doi: 10.1016/j.rbmo.2014.12.012.
Cai H., Niringiyumukiza J.D., Li Y., Lai Q., Su P., Xiang, W. Open versus closed vitrification system of human oocytes and embryos: a systematic review and meta-analysis of embryologic and clinical outcomes. Reproductive Biology and Endocrinology. 2018; 16 (123). Doi: 10.1186/s12958-018-0440-0.
Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertility Sterility. 2013; 99(1): 37-43. doi: 10.1016/j.fertnstert.2012.09.028.
Borges E., de Almeida Ferreira Braga D.P., de Sousa Bonetti T.C., Iaconelli A., Goncalves Franco J. Artificial oocyte activation with calcium ionophore A23187 in intracytoplasmic sperm injection cycles using surgically retrieved spermatozoa. Fertility Sterility. 2008; 92 (1): 131-136. Doi: 10.1016/j.fertnstert.2008.04.046
Ebner T., Oppelt P., Wober M., Staples P., Mayer R.B., Sonnleitner U et al. Treatment with Ca2+ ionophore improves embryo development and outcome in cases with previous developmental problems: a prospective multicenter study. Human Reproduction. 2014. Doi: 10.1093/humrep/deu285
Phan V.Y., Littman E., Harris D., La A. Pregnancy after the calcium ionophore activation and aneuploid screening using A-CGH in globozoospermia patient. Human Genetics and Embryology. 2015. http://dx.doi.org/10.4172/2161-0436.1000123.
Capalbo A., Ottolini C.S., Griffin D.K., Ubaldi F.M., Handyside A.H., Rienzi, L. Artificial oocyte activation with calcium ionophore does not cause a widespread increase in chromosome segregation errors in the second meiotic division of the oocyte. Fertility Sterility. 2016; 105(3): 807-813. http://dx.doi.org/10.1016/j.fertnstert.2015.11.017.
Additional Files
Published
How to Cite
Issue
Section
License
The articles published in this Journal are licensed under the CC BY-NC-ND 4.0 (Creative Commons Attribution – Non-Commercial – No Derivatives 4.0 International) license, which provides for their non-commercial use only. Under this license, users have the right to copy and distribute the material in copyright but are not permitted to modify or use it for commercial purposes. Full details on the licensing are available at https://creativecommons.org/licenses/by-nc-nd/4.0/.
